Argenx stock heads into the open after a 2.5% Nasdaq drop

At the close on September 9, 2026, Argenx stock finished at USD 1,007.07 on the Nasdaq, down 2.5% on the day as the broader market slipped. The shares also remained close to a reported 12-month high, with market cap above USD 62 billion.

Argenx stock closed at USD 1,007.07 on the Nasdaq on September 9, 2026, down 2.52% from the prior session according to Nasdaq data at Yahoo Finance. The move left the shares trading near a reported 12-month high around USD 1,072.75 and a market capitalization of about USD 62.20 billion on that date per Nasdaq figures cited by CompaniesMarketCap.

September 9, 2026 in numbers

Argenx SE (ISIN NL0010832176, Nasdaq: ARGX) saw its Nasdaq listing finish at USD 1,007.07 on September 9, 2026, with the close matching the session high and standing above the day low reported near USD 980, keeping the price within touching distance of the 52 week high around USD 1,072.75 per market data summaries. Nasdaq data at Yahoo Finance indicate the 2.52% loss came after the shares had closed at USD 1,033.15 on September 4, 2026, implying a decline of USD 26.08 over the last completed session and a modest pullback from recent gains. Per CompaniesMarketCap, Argenx carried a market capitalization of roughly USD 62.20 billion at the end of trading on September 9, 2026, underscoring that the stock remains one of the larger names in its biopharmaceutical peer group. Broader equity sentiment was weak, with the Dow Jones Industrial Average reported to have fallen 1.2% to 52,786.07 on September 9, 2026, highlighting that Argenx shares retreated into a softer overall tape rather than against a sharply rising market, as summarized in a US market wrap by Zacks.

Today’s drivers and upcoming events

Into today’s session on September 10, 2026, Argenx heads into the open without a newly reported company specific earnings release or scheduled investor event dated for the day in the available week long coverage, leaving overall biotech and large cap equity sentiment as likely influences on trading rather than a fresh fundamental data point tied specifically to the firm. Recent commentary on the name’s positioning has pointed to sustained analyst interest, with a consensus rating of Moderate Buy reaffirmed in an overview published on September 9, 2026 by MarketBeat, which highlighted that multiple covering firms continue to see upside potential over a longer horizon. Broader market conditions also matter for the stock today after the Dow Jones and other major US indices slipped in the last session, a backdrop that could keep attention on macroeconomic data releases and sector rotation dynamics rather than a single name specific catalyst, as described in the September 9, 2026 wrap by Zacks. With Argenx shares still close to their reported 12 month high and carrying a large capitalization, the stock may remain sensitive today to any sector wide news in biopharmaceuticals as well as shifts in overall risk appetite across the Nasdaq complex.